E75.25
Metachromatic leukodystrophy
Clinical Classification Guidelines
Medical Intelligence & Overview
Metachromatic leukodystrophy (MLD) is a rare, inherited disorder that affects the way the nervous system functions. It is caused by a deficiency of an enzyme called arylsulfatase A, leading to the buildup of fats that damage the myelin sheath — the protective covering around nerve fibers. This damage interferes with nerve communication, resulting in various neurological symptoms. MLD can present at different ages and progresses differently among individuals, but it is generally considered a serious condition requiring medical attention.
Causes & Symptoms
Clinical Causes: Genetic mutation affecting the ARSA gene Inheritance in an autosomal recessive pattern, meaning both parents carry the gene defect Absence or deficiency of the enzyme arylsulfatase A, leading to harmful fat accumulation in nerve cells
Key Symptoms: Progressive muscle weakness Loss of coordination and balance Difficulty walking or standing Problems with speech and swallowing Behavioral changes and intellectual decline Seizures Hearing and visual impairments Progressive paralysis in advanced stages
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, neurological examinations, and laboratory tests. Blood or skin cell tests measure enzyme activity levels. Genetic testing can identify mutations in the ARSA gene. MRI scans of the brain may show characteristic white matter changes consistent with demyelination. Early diagnosis is important to manage symptoms and plan treatment strategies.
Treatment Protocols: Currently, there is no known cure for MLD. Management mainly focuses on supportive care to improve quality of life. Approaches include physical therapy, occupational therapy, and speech therapy to maintain function. In some cases, hematopoietic stem cell transplantation may be attempted in early stages, though its effectiveness varies. Ongoing research is exploring gene therapy and enzyme replacement options that could offer future hope.
Clinical Advice & FAQs
Billing Guidance
Is E75.25 a billable ICD-10 code?
Yes, E75.25 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E75.25?
Clinical documentation must specify the nature of Metachromatic leukodystrophy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference